Yanchun Gao, Ruihong Wang, Lin Liu, Shitao Feng, Xiaozhi Xi, Wengong Yu, Yuchao Gu, Ye Wang
{"title":"Identification and characterization of shark VNARs targeting the <i>Helicobacter pylori</i> adhesin HpaA.","authors":"Yanchun Gao, Ruihong Wang, Lin Liu, Shitao Feng, Xiaozhi Xi, Wengong Yu, Yuchao Gu, Ye Wang","doi":"10.1080/21691401.2023.2255635","DOIUrl":null,"url":null,"abstract":"<p><p><i>Helicobacter pylori</i> (<i>H. pylori</i>) is recognized as a pathogen associated with several gastrointestinal diseases. The current treatments exhibit numerous drawbacks, including antibiotic resistance. <i>H. pylori</i> can adhere to and colonize the gastric mucosa through <i>H. pylori</i> adhesin A (HpaA), and antibodies against HpaA may be an effective therapeutic approach. The variable domain of immunoglobulin new antigen receptor (VNAR) is a novel type of single-domain antibody with a small size, good stability, and easy manufacturability. This study isolated VNARs against HpaA from an immune shark VNAR phage display library. The VNARs can bind both recombinant and native HpaA proteins. The VNARs, 2A2 and 3D6, showed high binding affinities to HpaA with different epitopes. Furthermore, homodimeric bivalent VNARs, biNb-2A2 and biNb-3D6, were constructed to enhance the binding affinity. The biNb-2A2 and biNb-3D6 had excellent stability at gastrointestinal pH conditions. Finally, a sandwich ELISA assay was developed to quantify the HpaA protein using BiNb-2A2 as the capture antibody and BiNb-3D6 as the detection antibody. This study provides a potential foundation for novel alternative approaches to treatment or diagnostics applications of <i>H. pylori</i> infection.</p>","PeriodicalId":8736,"journal":{"name":"Artificial Cells, Nanomedicine, and Biotechnology","volume":"51 1","pages":"509-519"},"PeriodicalIF":4.5000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Artificial Cells, Nanomedicine, and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/21691401.2023.2255635","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Helicobacter pylori (H. pylori) is recognized as a pathogen associated with several gastrointestinal diseases. The current treatments exhibit numerous drawbacks, including antibiotic resistance. H. pylori can adhere to and colonize the gastric mucosa through H. pylori adhesin A (HpaA), and antibodies against HpaA may be an effective therapeutic approach. The variable domain of immunoglobulin new antigen receptor (VNAR) is a novel type of single-domain antibody with a small size, good stability, and easy manufacturability. This study isolated VNARs against HpaA from an immune shark VNAR phage display library. The VNARs can bind both recombinant and native HpaA proteins. The VNARs, 2A2 and 3D6, showed high binding affinities to HpaA with different epitopes. Furthermore, homodimeric bivalent VNARs, biNb-2A2 and biNb-3D6, were constructed to enhance the binding affinity. The biNb-2A2 and biNb-3D6 had excellent stability at gastrointestinal pH conditions. Finally, a sandwich ELISA assay was developed to quantify the HpaA protein using BiNb-2A2 as the capture antibody and BiNb-3D6 as the detection antibody. This study provides a potential foundation for novel alternative approaches to treatment or diagnostics applications of H. pylori infection.
幽门螺杆菌(Helicobacter pylori, H. pylori)被认为是一种与多种胃肠道疾病相关的病原体。目前的治疗方法有许多缺点,包括抗生素耐药性。幽门螺杆菌可通过幽门螺杆菌粘连素A (HpaA)粘附胃黏膜并定植,抗HpaA抗体可能是治疗幽门螺杆菌的有效途径。免疫球蛋白新抗原受体可变结构域(variable domain of immunoglobulin new antigen receptor, VNAR)是一种体积小、稳定性好、易于制造的新型单域抗体。本研究从免疫鲨鱼VNAR噬菌体展示文库中分离出抗HpaA的VNAR。vnas可以结合重组蛋白和天然HpaA蛋白。vnas 2A2和3D6对不同表位的HpaA具有较高的结合亲和力。此外,构建了二价同源二聚体vnas biNb-2A2和biNb-3D6,以增强其结合亲和力。biNb-2A2和biNb-3D6在胃肠道pH条件下具有良好的稳定性。最后,以BiNb-2A2为捕获抗体,BiNb-3D6为检测抗体,建立夹心ELISA法定量HpaA蛋白。本研究为幽门螺杆菌感染的治疗或诊断提供了新的替代方法的潜在基础。
期刊介绍:
Artificial Cells, Nanomedicine and Biotechnology covers the frontiers of interdisciplinary research and application, combining artificial cells, nanotechnology, nanobiotechnology, biotechnology, molecular biology, bioencapsulation, novel carriers, stem cells and tissue engineering. Emphasis is on basic research, applied research, and clinical and industrial applications of the following topics:artificial cellsblood substitutes and oxygen therapeuticsnanotechnology, nanobiotecnology, nanomedicinetissue engineeringstem cellsbioencapsulationmicroencapsulation and nanoencapsulationmicroparticles and nanoparticlesliposomescell therapy and gene therapyenzyme therapydrug delivery systemsbiodegradable and biocompatible polymers for scaffolds and carriersbiosensorsimmobilized enzymes and their usesother biotechnological and nanobiotechnological approachesRapid progress in modern research cannot be carried out in isolation and is based on the combined use of the different novel approaches. The interdisciplinary research involving novel approaches, as discussed above, has revolutionized this field resulting in rapid developments. This journal serves to bring these different, modern and futuristic approaches together for the academic, clinical and industrial communities to allow for even greater developments of this highly interdisciplinary area.